NSE மற்றும் BSE-யின் ஒவ்வொரு கார்ப்பரேட் அறிவிப்பும், AI-யால் சில நிமிடங்களில் படிக்கப்பட்டு விளக்கப்படுகிறது — தாக்கம், முக்கிய புள்ளிவிவரங்கள், குறுகிய/நீண்டகாலப் பார்வை, கவனிக்க வேண்டியவை.
நேரலைசமீபத்திய அறிவிப்பு: 7 நாட்களுக்கு முன்இன்று 0 பகுப்பாய்வு செய்யப்பட்டது
குறிப்பு: இவை NSE பொது அறிக்கைகளின் AI-உருவாக்கிய, கல்வி நோக்கச் சுருக்கங்கள் — ஒவ்வொரு ஆவணத்தையும் ஆதாரமாகக் கொண்டவை, ஆனால் முதலீட்டு ஆலோசனை அல்ல, மேலும் முழுமையற்றதாகவும் இருக்கலாம். அசல் அறிக்கையுடன் சரிபார்க்கவும், செயல்படுவதற்கு முன் SEBI-பதிவு பெற்ற முதலீட்டு ஆலோசகரை அணுகவும்.
Q2 FY27 Revenue at ₹79.39 Cr; Auditors Flag Going Concern Risk on SARFAESI Demand
Mangalam Drugs reported consolidated revenue from operations of ₹79.39 crore for Q2 FY27, up 61% YoY compared to ₹49.26 crore in Q2 FY26. However, statutory auditors highlighted material uncertainty regarding the company's ability to continue as a going concern. Borrowings from Bank of Maharashtra and Bank of Baroda totaling ₹55.57 crore are classified as NPAs, with Bank of Baroda issuing a SARFAESI demand notice of ₹26.72 crore on September 23, 2026. Furthermore, current liabilities exceed current assets by ₹45.21 crore as of September 30, 2026.
உச்சம் நம்பிக்கை
என்ன மாறியதுMangalam Drugs announced its Q2 FY27 results, accompanied by an auditor going concern qualification over debt defaults and a SARFAESI demand notice.
ஏன் இது முக்கியம்With NPA classifications on ₹55.57 crore debt (more than its market cap of ₹48 crore) and net working capital deficit of ₹45.21 crore, the company faces severe liquidity stress and potential asset recovery actions by lenders.
Q2 FY27 Revenue: ₹7,939.24 லட்சம்NPA Debt Outstanding: ₹5,556.52 லட்சம்SARFAESI Demand Notice: ₹2,671.57 லட்சம்Excess of Current Liabilities over Assets: ₹4,521.21 லட்சம்NPA Debt vs Market Cap: ~116%
📅 குறுகிய காலம்Heightened stock volatility is expected as legal and recovery risks escalate following Bank of Baroda's SARFAESI notice.
📈 நீண்ட காலம்The company's survival and continuity depend on successful debt restructuring with lenders, especially amidst negative TTM profitability and working capital stress.
⚠ அபாய எச்சரிக்கைகள்
Going concern material uncertainty flagged by auditors
SARFAESI Section 13(2) demand notice from Bank of Baroda
Consortium bank facilities classified as Non-Performing Assets
Severe working capital deficit with current liabilities exceeding current assets by ₹45.21 crore
👀 கவனிக்க வேண்டியவை
Track the outcome of debt resolution discussions with consortium lenders and the company's formal response to Bank of Baroda's SARFAESI demand notice.
Mangalam Drugs Reports Rs 15.57 Cr Bank Loan Default Exceeding 30 Days
Mangalam Drugs and Organics disclosed continuing loan defaults exceeding 30 days on its cash credit accounts with Bank of Maharashtra and Bank of Baroda. The total overdue amount stands at Rs 15.57 Cr (Rs 1,557.27 Lacs) as of October 15, 2026. Defaults originated in October 2025 (October 17 for Bank of Maharashtra and October 20 for Bank of Baroda). This overdue amount equals approximately 31.8% of the company's Rs 49 Cr market capitalization, highlighting severe ongoing liquidity stress.
உச்சம் நம்பிக்கை
என்ன மாறியதுFormal subsequent disclosure confirming ongoing default on revolving credit lines with two public sector banks lasting nearly a full year.
ஏன் இது முக்கியம்The defaulted amount represents ~31.8% of market cap and ~14.8% of total debt (Rs 105 Cr), compounding pressure on a company already reporting TTM net losses of Rs -44 Cr.
Bank of Maharashtra Overdue: Rs 951.19 LacsBank of Baroda Overdue: Rs 606.08 LacsTotal Overdue Amount: Rs 15.57 கோடிTotal Overdue vs Market Cap: ~31.8%Total Overdue vs Debt (Rs 105 Cr): ~14.8%
📅 குறுகிய காலம்Negative sentiment and elevated risk of formal recovery actions or asset freezes by Bank of Maharashtra and Bank of Baroda.
📈 நீண்ட காலம்Heightened insolvency risk if credit lines remain frozen, which impairs raw material procurement and delays operational turnaround.
⚠ அபாய எச்சரிக்கைகள்
Loan default / credit rating downgrade risk
Severe liquidity crunch with TTM net loss of Rs -44 Cr
Possible NCLT/SARFAESI recovery actions by lenders
👀 கவனிக்க வேண்டியவை
Track lender actions regarding debt restructuring or potential recovery/NCLT proceedings, and monitor Q2 FY27 cash flows to assess working capital solvency.
Mangalam Drugs Reports Rs 15.57 Cr Bank Overdue Across Bank of Maharashtra & Bank of Baroda
Mangalam Drugs and Organics has disclosed continuing defaults on cash credit facilities with Bank of Maharashtra and Bank of Baroda exceeding 30 days. As of September 14, 2026, total overdue amounts stand at Rs 15.57 crore, comprising Rs 951.19 lakh to Bank of Maharashtra (defaulted since Oct 17, 2025) and Rs 606.08 lakh to Bank of Baroda (defaulted since Oct 20, 2025). The total overdue accounts for nearly 29% of the company's current market capitalization of Rs 53 crore, highlighting severe liquidity pressure following TTM losses of Rs 44 crore.
உச்சம் நம்பிக்கை
என்ன மாறியதுMangalam Drugs filed a subsequent intimation disclosing continuous cash credit defaults exceeding 30 days totaling Rs 15.57 crore across two public sector banks.
ஏன் இது முக்கியம்The company has posted four consecutive loss-making quarters (TTM net profit of Rs -44 crore) with total debt of Rs 105 crore; unresolved bank defaults jeopardize working capital access and operational solvency.
Bank of Maharashtra Overdue: Rs 951.19 LacsBank of Baroda Overdue: Rs 606.08 LacsTotal Overdue Amount: Rs 15.57 கோடிTotal Overdue vs Market Cap: ~29.4%Total Overdue vs Total Debt: ~14.8%
📅 குறுகிய காலம்Heightened credit risk and potential punitive actions from lenders, including classification as NPA or issuance of loan recall notices.
📈 நீண்ட காலம்Unless working capital is restored and operating profitability recovers, extended defaults could lead to NCLT insolvency proceedings or loss of creditor support.
⚠ அபாய எச்சரிக்கைகள்
Prolonged debt default (>10 months since October 2025)
Severe liquidity crunch with TTM net losses of Rs 44 crore
Risk of legal or recovery action under SARFAESI or IBC by lenders
👀 கவனிக்க வேண்டியவை
Track whether the company succeeds in regularizing these accounts or restructuring its debt, as persistent defaults risk formal recovery or insolvency (IBC) proceedings by lending banks.
₹7.55 Cr Net Loss in Q1 FY27; Mangalam Drugs Appoints New Statutory Auditors for 5-Year Term
Mangalam Drugs reported a net loss of ₹7.55 Cr for Q1 FY27, showing a narrowing of losses compared to the ₹13.73 Cr loss in Q1 FY26. Revenue from operations remained stagnant at ₹57.12 Cr, while finance costs of ₹3.68 Cr continue to weigh on the bottom line. The Board has proposed M/s S.N. Nanda & Co. as the new Statutory Auditors for a five-year term (FY27-FY31), subject to shareholder approval. The company remains in a precarious financial position with a Debt-to-Equity ratio of 1.02 and a market cap of only ₹43 Cr against ₹105 Cr in debt.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company reported its first-quarter results for FY27 and initiated a transition to new statutory and secretarial auditors for the next five years.
ஏன் இது முக்கியம்The narrowing of losses is a slight operational improvement, but the company's high debt (₹105 Cr) relative to its market cap (₹43 Cr) and continued negative EPS (-₹4.77) indicate significant financial stress.
Q1 Net Loss: ₹7.55 கோடிQ1 வருவாய்: ₹57.12 கோடிFinance Costs: ₹3.68 கோடிDebt-to-Equity Ratio: 1.02Auditor Term: 5 years
📅 குறுகிய காலம்The stock is likely to remain volatile and under pressure given the continued losses and high interest burden, despite the year-on-year reduction in net loss.
📈 நீண்ட காலம்Long-term recovery is contingent on the successful integration of merged entities and a turnaround in the API market, specifically for anti-malarial and anti-retroviral products.
⚠ அபாய எச்சரிக்கைகள்
High debt-to-equity ratio (1.02)
Persistent net losses
Reliance on international funding agencies for end-user demand
Negative interest coverage
👀 கவனிக்க வேண்டியவை
Investors should monitor the NCLT hearing progress for the pending mergers and watch for any improvement in operating margins, as the company is currently struggling with negative profitability and high debt levels.
Mangalam Drugs Q1 Loss Narrows to ‡7.55 Cr; Revenue Stagnant at ‡57.12 Cr
Mangalam Drugs reported a stagnant top-line for Q1 FY27, with revenue from operations at ‡57.12 Cr compared to ‡57.21 Cr in the previous year's quarter. However, the company saw a significant 45% reduction in net loss, which narrowed to ‡7.55 Cr from ‡13.73 Cr YoY. This improvement was driven by a 9% reduction in total expenses, primarily through better inventory management and lower material costs. The company remains in a precarious financial position with a market cap of only ‡42 Cr against a TTM loss of ‡44 Cr.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company has significantly reduced its quarterly burn rate despite stagnant revenues, while also overhauling its statutory and secretarial auditors.
ஏன் இது முக்கியம்For a micro-cap company with high debt (D/E 1.02) and a market cap lower than its quarterly revenue, narrowing losses is a critical first step toward avoiding further equity erosion.
Revenue (Q1 FY27): ‡57.12 CrNet Loss (Q1 FY27): ‡7.55 CrQuarterly Revenue vs Market Cap: 136%TTM Net Profit: ‡-44 CrDebt-to-Equity: 1.02
📅 குறுகிய காலம்The narrowing of losses may provide a temporary floor to the stock price, but the lack of revenue growth remains a concern.
📈 நீண்ட காலம்The long-term outlook depends entirely on the successful execution of the merger and the company's ability to pivot away from low-margin API segments affected by US-AID funding cuts.
⚠ அபாய எச்சரிக்கைகள்
Persistent net losses
High debt relative to market capitalization
Stagnant revenue growth
Concentration risk in institutional-funded API markets
👀 கவனிக்க வேண்டியவை
Investors should monitor the progress of the pending merger with Mangalam Laboratories and Shri JB Pharma, and watch for any stabilization in operating margins which remain negative.
📊 கடந்த 7 நாட்கள் — உணர்வு அடிப்படையில் பகுப்பாய்வு செய்யப்பட்ட அறிவிப்புகள்
₹15.57 Cr Default: Mangalam Drugs Reports Ongoing Loan Defaults Since October 2025
Mangalam Drugs and Organics has disclosed a persistent default on its cash credit facilities with Bank of Maharashtra and Bank of Baroda. As of July 15, 2026, the total overdue amount stands at ₹15.57 Cr, with defaults originating as far back as October 17, 2025. This prolonged default highlights severe liquidity stress, coinciding with a TTM net loss of ₹44 Cr and a negative operating margin of -6.5%.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company has officially quantified and reported a long-standing default on its working capital loans that has exceeded the 30-day regulatory reporting threshold.
ஏன் இது முக்கியம்Persistent defaults on working capital facilities are a critical indicator of insolvency risk. Given the company's negative ROCE of -14.0% and high debt-to-equity ratio of 1.02, these defaults threaten the company's operational viability and credit standing.
Total Overdue Amount: ₹15.57 கோடிOverdue vs Net Worth: ~15.1%Overdue vs TTM Revenue: ~6.7%Bank of Maharashtra Overdue: ₹951.19 லட்சம்Bank of Baroda Overdue: ₹606.08 லட்சம்
📅 குறுகிய காலம்Negative. The market is likely to react poorly to the confirmation of a multi-month default, which suggests the company is struggling to meet even its basic interest and principal obligations.
📈 நீண்ட காலம்Structural concern. Unless the company can successfully restructure its debt or significantly improve its margins (currently -6.5%), it faces a high risk of being referred to the NCLT by its lenders.
⚠ அபாய எச்சரிக்கைகள்
Insolvency risk
Liquidity crunch
Potential legal action by lenders
Deteriorating financial health (TTM PAT -₹44 Cr)
👀 கவனிக்க வேண்டியவை
Investors should closely monitor for any legal actions initiated by lenders under the SARFAESI Act or insolvency proceedings. The company's ability to complete its pending merger with Mangalam Laboratories and Shri JB Pharma may be significantly compromised by these defaults.
Rs 15.57 Cr Default: Mangalam Drugs Reports Continued Non-Payment to BoM and BoB
Mangalam Drugs and Organics has disclosed a persistent default on its cash credit facilities with Bank of Maharashtra and Bank of Baroda, totaling Rs 15.57 Cr as of June 15, 2026. These defaults originated in October 2025, indicating a long-standing liquidity crisis that has now exceeded the 30-day regulatory reporting threshold. With a TTM net loss of Rs 44 Cr and a debt-to-equity ratio of 1.02, the company's financial position is under severe strain. The overdue amount represents approximately 15% of the company's total debt of Rs 105 Cr.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company has formally acknowledged that its default on bank loan obligations has persisted for over 30 days, specifically since October 2025.
ஏன் இது முக்கியம்Persistent defaults on working capital facilities (Cash Credit) suggest severe cash flow issues, which could lead to banks freezing accounts or initiating recovery proceedings under the Insolvency and Bankruptcy Code (IBC).
Total Overdue: Rs 15.57 கோடிOverdue vs Total Debt: ~14.8%TTM Net Loss: Rs 44 கோடிDebt-to-Equity: 1.02Default Start Date (BoM): 17/10/2025
📅 குறுகிய காலம்Negative; the stock is likely to face significant downward pressure as the risk of insolvency or bank-led recovery actions increases.
📈 நீண்ட காலம்The company's long-term viability depends on a successful turnaround of its API business and the completion of its planned merger to stabilize the balance sheet.
⚠ அபாய எச்சரிக்கைகள்
Liquidity risk
Insolvency risk
Persistent operational losses
High debt-to-equity ratio
👀 கவனிக்க வேண்டியவை
Investors should closely monitor any legal actions initiated by the banks and the progress of the NCLT merger hearing, which is critical for the company's survival strategy.
Mangalam Drugs Defaults on ₹15.58 Crore Loan Obligations to Bank of Maharashtra & Bank of Baroda
Mangalam Drugs and Organics Limited has officially disclosed a default on its cash credit facilities with two major lenders, Bank of Maharashtra and Bank of Baroda. As of May 15, 2026, the total overdue amount stands at ₹1,558.05 Lacs, with defaults originating as far back as October 2025. The company has exceeded the 30-day grace period for revolving facilities, necessitating this mandatory SEBI disclosure. Management has stated they are making arrangements to settle the overdue amounts as soon as possible.
முக்கிய அம்சங்கள்
Total overdue amount of ₹1,558.05 Lacs (approx. ₹15.58 Crores) across two bank accounts.Default of ₹951.97 Lacs with Bank of Maharashtra outstanding since October 17, 2025.Default of ₹606.08 Lacs with Bank of Baroda outstanding since October 20, 2025.Disclosure triggered under SEBI Regulation 30 due to defaults exceeding 30 days in revolving facilities.
👀 கவனிக்க வேண்டியவை
Investors should exercise extreme caution as persistent loan defaults indicate significant liquidity issues and potential insolvency risks. Closely monitor for any further credit rating downgrades or legal actions initiated by the lending banks.
Mangalam Drugs Reports ₹43.81 Cr Net Loss in FY26 as Revenue Drops 27% YoY
Mangalam Drugs and Organics Limited reported a weak set of numbers for the financial year ended March 31, 2026, shifting from profitability to a substantial loss. Annual revenue from operations declined by nearly 27% to ₹232.13 crore, down from ₹317.58 crore in the previous fiscal year. The company posted a net loss of ₹43.81 crore for the full year, compared to a net profit of ₹6.92 crore in FY25. This downturn was primarily driven by a sharp contraction in margins as total expenses significantly exceeded total income.
முக்கிய அம்சங்கள்
Annual Revenue from Operations fell 26.9% YoY to ₹23,213.27 Lakhs.Net Loss for FY26 stood at ₹4,381.42 Lakhs compared to a Net Profit of ₹692.43 Lakhs in FY25.Q4 FY26 standalone loss widened to ₹1,306.04 Lakhs from a profit of ₹15.09 Lakhs in Q4 FY25.Earnings Per Share (EPS) for the full year dropped to ₹(27.68) from ₹4.37 in the previous year.Total Equity reduced to ₹10,332.21 Lakhs from ₹14,865.61 Lakhs year-on-year due to accumulated losses.
👀 கவனிக்க வேண்டியவை
Investors should exercise extreme caution as the company has moved into a significant loss-making position with declining revenues. It is advisable to wait for management's commentary on recovery strategies and cost-optimization measures before considering any new investment.
Mangalam Drugs Defaults on Rs 15.58 Crore Loan Obligations to BoM and BoB
Mangalam Drugs and Organics Limited has officially disclosed a default on its loan obligations to Bank of Maharashtra and Bank of Baroda. The total overdue amount across two cash credit accounts is approximately Rs. 15.58 Crores. These defaults originated in October 2025 and have remained unresolved for over 30 days, triggering mandatory disclosure under SEBI regulations. While management claims to be arranging funds for repayment, the persistent nature of the default signals significant liquidity pressure.
முக்கிய அம்சங்கள்
Total default amount of approximately Rs. 15.58 Crores across two nationalized banks.Overdue amount of Rs. 951.97 Lacs with Bank of Maharashtra since October 17, 2025.Overdue amount of Rs. 606.08 Lacs with Bank of Baroda since October 20, 2025.Defaults on revolving cash credit facilities have persisted for over six months as of the April 2026 filing.
👀 கவனிக்க வேண்டியவை
Investors should exercise extreme caution as persistent loan defaults indicate severe liquidity issues and potential insolvency risks. It is advisable to monitor for credit rating downgrades and avoid fresh positions until debt resolution is confirmed.
Mangalam Drugs Defaults on ₹15.85 Crore Bank Loans to Bank of Baroda and Bank of Maharashtra
Mangalam Drugs and Organics Limited has officially disclosed a default on its loan obligations to Bank of Baroda and Bank of Maharashtra. The total overdue amount as of March 15, 2026, is ₹1,585.29 Lacs (approximately ₹15.85 Crores). These defaults have persisted since mid-October 2025, exceeding the 30-day threshold for mandatory SEBI disclosure. The company has stated it is making arrangements to settle the overdue amounts as soon as possible.
முக்கிய அம்சங்கள்
Default on Bank of Maharashtra cash credit account for ₹979.21 Lacs since October 17, 2025Default on Bank of Baroda account for ₹606.08 Lacs since October 20, 2025Total combined overdue amount stands at ₹1,585.29 Lacs as of March 15, 2026Disclosure triggered under SEBI Regulation 30 for defaults exceeding 30 days
👀 கவனிக்க வேண்டியவை
Investors should exercise extreme caution as persistent loan defaults indicate severe liquidity issues and risk of credit rating downgrades. Monitor for any updates on debt repayment or potential insolvency proceedings.
Mangalam Drugs Defaults on Rs 15.85 Crore Bank Loan Payments
Mangalam Drugs and Organics Limited has reported a continued default on its cash credit facilities with Bank of Maharashtra and Bank of Baroda. As of February 15, 2026, the total overdue amount stands at Rs 15.85 Crores, with defaults originating in October 2025. This disclosure follows the 30-day threshold for revolving facilities where outstanding balances exceed sanctioned limits. While the company claims to be arranging funds for repayment, the persistent nature of these defaults signals significant liquidity stress.
முக்கிய அம்சங்கள்
Total overdue amount of Rs 15.85 Crores across two major bank accounts as of Feb 15, 2026Default of Rs 979.21 Lacs to Bank of Maharashtra starting from October 17, 2025Default of Rs 606.08 Lacs to Bank of Baroda starting from October 20, 2025Defaults involve revolving cash credit facilities that have remained over-limit for more than 30 days
👀 கவனிக்க வேண்டியவை
Investors should exercise extreme caution as persistent debt defaults are a major red flag for financial health and potential insolvency. It is advisable to monitor for any further credit rating downgrades or recovery actions by the lenders.
Mangalam Drugs Appoints Jeevan M. Dalvi as CFO; Re-appoints Independent Director
Mangalam Drugs and Organics Limited has announced key leadership changes, including the appointment of Mr. Jeevan M. Dalvi as the new Chief Financial Officer effective February 6, 2026. Mr. Dalvi brings over 20 years of experience in finance and accounts, specializing in cost-saving measures. Additionally, the board approved the re-appointment of Dr. Praveen Saxena as an Independent Director for a second five-year term starting March 2026. These updates follow the resignation of Independent Director Shri Rukmesh P. Dhandhania, who retired from professional responsibilities in January 2026.
முக்கிய அம்சங்கள்
Appointment of Mr. Jeevan M. Dalvi as CFO effective February 6, 2026, with 20+ years of experience.Re-appointment of Dr. Praveen Saxena as Independent Director for a 5-year term until March 2031.Resignation of Shri Rukmesh P. Dhandhania as Independent Director effective January 16, 2026.New CFO expertise focuses on financial advisory, cost-saving, and process improvement.
👀 கவனிக்க வேண்டியவை
Investors should monitor the new CFO's impact on the company's financial processes and cost management. The re-appointment of an experienced director provides stability to the board's strategic oversight.
CRISIL Downgrades Mangalam Drugs to 'D' (Default) Rating on Rs 115 Cr Bank Facilities
CRISIL has downgraded Mangalam Drugs and Organics Limited's credit rating to 'CRISIL D' for its Rs 115 crore bank facilities, indicating the company is in default. The downgrade stems from the company overdrawing cash credit facilities for more than 30 days and defaulting on Covid loan payments. Additionally, the company has been tagged as 'Issuer Not Cooperating' due to its failure to provide necessary financial information and alleged misrepresentation of its debt-servicing ability in October 2025. Financial health has severely weakened, with the company reporting a net loss of Rs 13.73 crore for the quarter ending June 2025.
முக்கிய அம்சங்கள்
Ratings for Rs 115 crore bank facilities downgraded to 'CRISIL D' from 'CRISIL BB+/Stable'.Company defaulted on Covid loans and overextended cash credit facilities for over 30 days.Classified as 'Issuer Not Cooperating' after failing to respond to multiple CRISIL communications since October 2025.Reported a significant net loss of Rs 13.73 crore and negative operating margins of -7.85% in June 2025.CRISIL highlighted misrepresentation in the company's No Default Statement (NDS) regarding its ability to honor October 2025 obligations.
👀 கவனிக்க வேண்டியவை
Investors should exercise extreme caution as a 'D' rating signifies a default on debt obligations and high credit risk. The allegations of misrepresentation and lack of management cooperation are serious corporate governance red flags.
Mangalam Drugs Defaults on ₹15.56 Crore Bank Loan Payments to BoM and BoB
Mangalam Drugs and Organics Limited has reported a default on its loan obligations to Bank of Maharashtra and Bank of Baroda. The total overdue amount as of January 15, 2026, stands at ₹15.56 Crores across two cash credit accounts. The defaults began in mid-October 2025 and have persisted for over 30 days, triggering mandatory SEBI disclosure requirements. The company has stated it is making arrangements to settle the overdue amounts as soon as possible.
முக்கிய அம்சங்கள்
Total overdue amount of ₹1555.63 Lacs (₹15.56 Crores) across two major banksDefault of ₹1040.71 Lacs to Bank of Maharashtra starting from October 17, 2025Default of ₹514.92 Lacs to Bank of Baroda starting from October 20, 2025The defaults involve Cash Credit facilities where balances exceeded limits for over 30 days
👀 கவனிக்க வேண்டியவை
Investors should exercise extreme caution as persistent defaults indicate severe liquidity issues and potential credit rating downgrades. Monitor the company's ability to raise funds or restructure debt to clear these dues.
Mangalam Drugs and Organics Limited has announced the resignation of its Chief Financial Officer, Mr. Ajay Avinash Samant, effective January 31, 2026, citing health reasons. Simultaneously, the Company Secretary and Compliance Officer, Ms. Anuradha Pandey, has also tendered her resignation. These leadership changes were approved during a board meeting on January 15, 2026, where the company also cleared its unaudited financial results for the quarter. Notably, the statutory auditors have issued an unmodified opinion on the financial statements, suggesting no immediate accounting concerns despite the management churn.
முக்கிய அம்சங்கள்
CFO Ajay Samant to step down effective January 31, 2026, following his resignation letter dated November 5, 2025.Company Secretary Anuradha Pandey resigned on January 2, 2026, creating a dual vacancy in Key Managerial Personnel (KMP).The Board approved unaudited standalone and consolidated financial results for the quarter ended January 15, 2026.Statutory auditors expressed an unmodified opinion on the financial results, indicating no major audit qualifications.The Board meeting concluded at 2:30 P.M. on January 15, 2026, after transacting these key management and financial items.
👀 கவனிக்க வேண்டியவை
Investors should monitor the company's upcoming appointments for the CFO and CS roles to ensure continuity in financial oversight and compliance. While the clean audit report is a positive sign, the simultaneous exit of two key officers warrants a cautious approach toward corporate governance.
Mangalam Drugs Reports Q3 Net Loss of ₹4.41 Cr; CFO and Company Secretary Resign
Mangalam Drugs and Organics reported a poor financial performance for Q3 FY26, posting a consolidated net loss of ₹4.41 crore compared to a profit of ₹3.51 crore in the same period last year. Revenue from operations saw a sharp decline of 34% YoY, falling to ₹58.49 crore from ₹88.71 crore. Adding to the financial stress, the company announced the resignations of its Chief Financial Officer, Ajay Samant, and Company Secretary, Anuradha Pandey. For the nine-month period ending December 2025, the company has accumulated a total net loss of ₹16.73 crore.
முக்கிய அம்சங்கள்
Consolidated revenue from operations fell 34% YoY to ₹58.49 crore in Q3 FY26.Reported a net loss of ₹4.41 crore for the quarter versus a profit of ₹3.51 crore in Q3 FY25.Total expenses of ₹64.38 crore exceeded total income for the quarter, leading to operational losses.CFO Ajay Samant resigned effective January 31, 2026, citing health reasons.Company Secretary Anuradha Pandey resigned effective March 29, 2026, to pursue other opportunities.
👀 கவனிக்க வேண்டியவை
Investors should exercise caution as the company is facing both financial losses and a vacuum in key managerial positions. The significant YoY revenue drop and transition to a net loss suggest fundamental operational challenges.
Mangalam Drugs Reports Q3 Revenue Decline to ₹58.49 Cr; CFO and CS Resign
Mangalam Drugs and Organics reported a significant decline in consolidated revenue for Q3 FY26, falling to ₹58.49 crore from ₹88.71 crore in the same quarter last year. The company faced an operational loss as total expenses of ₹64.38 crore exceeded its total income for the quarter. Adding to the financial pressure, the company announced the resignations of two Key Managerial Personnel: the Chief Financial Officer (CFO) and the Company Secretary. The 9-month performance also shows a sharp downward trend, with revenue dropping nearly 32% year-on-year.
முக்கிய அம்சங்கள்
Consolidated revenue for Q3 FY26 fell 34% YoY to ₹58.49 crore from ₹88.71 crore.Total expenses for the quarter stood at ₹64.38 crore, leading to an operational loss before other income and tax.9-month revenue for FY26 declined to ₹165.38 crore compared to ₹245.19 crore in the previous year period.CFO Ajay Samant resigned effective January 31, 2026, citing health reasons.Company Secretary Anuradha Pandey resigned effective March 29, 2026, to pursue other opportunities.
👀 கவனிக்க வேண்டியவை
Investors should exercise caution as the company is struggling with both declining top-line performance and the simultaneous exit of key leadership. It is advisable to wait for signs of operational stabilization and the appointment of new management before considering new positions.
Mangalam Drugs Defaults on ₹11.54 Crore Loan Payments to PSU Banks
Mangalam Drugs and Organics Limited has reported a subsequent default on its cash credit facilities with Bank of Baroda and Bank of Maharashtra. As of December 17, 2025, the total overdue amount stands at ₹1,153.76 Lacs. The default has persisted for more than 30 days, triggering mandatory disclosure under SEBI (LODR) Regulations. The company's management has stated that they are making arrangements to settle the overdue amounts as soon as possible.
முக்கிய அம்சங்கள்
Total overdue amount of ₹1,153.76 Lacs across two major public sector banksDefault of ₹707.05 Lacs to Bank of Maharashtra on cash credit accountDefault of ₹446.71 Lacs to Bank of Baroda on cash credit accountDefault duration has exceeded the 30-day threshold for revolving facilitiesManagement is currently arranging funds to clear the outstanding dues
👀 கவனிக்க வேண்டியவை
Investors should exercise extreme caution as loan defaults indicate severe liquidity stress and potential solvency issues. Monitor for any further credit rating downgrades or legal actions by the lending banks.
Mangalam Drugs Defaults on Rs 11.54 Crore Loan Payments to PSU Banks
Mangalam Drugs and Organics Limited has officially disclosed defaults on its cash credit facilities with Bank of Maharashtra and Bank of Baroda. The total overdue amount is approximately Rs 11.54 crore, which has remained unpaid for over 30 days. Specifically, the company owes Rs 7.07 crore to Bank of Maharashtra and Rs 4.47 crore to Bank of Baroda. Management has indicated that they are currently making arrangements to settle these overdue amounts as soon as possible.
முக்கிய அம்சங்கள்
Total default amount of Rs 11.54 crore reported across two bank accounts.Rs 707.05 Lacs overdue to Bank of Maharashtra with default starting October 17, 2025.Rs 446.77 Lacs overdue to Bank of Baroda with default starting October 20, 2025.Defaults have persisted for more than 30 days, triggering mandatory SEBI disclosure requirements.The company is currently seeking arrangements to clear the outstanding dues.
👀 கவனிக்க வேண்டியவை
Investors should exercise extreme caution as debt defaults are a major red flag indicating severe liquidity stress. Monitor for potential credit rating downgrades and the company's ability to clear these dues in the immediate term.
⚠️இந்தத் தளம் எவ்வாறு உருவாக்கப்படுகிறது: சந்தைத் தரவுப் பக்கங்கள் NSE/BSE வெளியீடுகள் மற்றும் நிறுவனங்களின் தாக்கல்களிலிருந்து தானாகக் கணக்கிடப்படுகின்றன; செய்திக் கட்டுரைகளும் அறிவிப்புப் பகுப்பாய்வுகளும் AI உதவியுடன் எழுதப்படுகின்றன, மனித மேற்பார்வையுடன்: AI உருவாக்குவதை எங்கள் ஆசிரியர்கள் மதிப்பாய்வு செய்கின்றனர். இரண்டிலும் பிழைகள் இருக்கலாம். எந்தவொரு முதலீட்டு முடிவுக்கு முன்பும் அசல் மூலங்களில் சரிபார்க்கவும். முதலீட்டு ஆலோசனை அல்ல; Flash Finance SEBI-பதிவு பெற்றது அல்ல. நாங்கள் AI-ஐ எவ்வாறு பயன்படுத்துகிறோம்
🎁 ஆரம்பகால ஆதரவாளர்களுக்கு மட்டும் · குறுகிய கால சலுகை
எங்கள் AI பங்குச் சந்தை பகுப்பாய்வு: டெலிகிராம், வாட்ஸ்அப்பில் இலவசம்
⚡ 3500+ நிறுவனங்களை நாங்கள் உடனுக்குடன் கண்காணிக்கிறோம். NSE-யில் ஒரு நிறுவன அறிவிப்பு வெளியானதுமே, எங்கள் AI அதைப் படித்து, சுருக்கி, அதன் தாக்கத்தைச் சில நொடிகளில் உங்களுக்குச் சொல்கிறது.
இதுபோன்ற AI பகுப்பாய்வுக்குக் கட்டணத் தளங்கள் ஆண்டுக்கு ₹1,00,000-க்கும் மேல் வசூலிக்கின்றன. எங்கள் சேனல்களில் இது இலவசம்.
